Total Payments
$2,465
2024 Payments
$74.69
Companies
29
Transactions
97
Medicare Patients
4,475
Medicare Billing
$1.6M
Payment Breakdown by Category
Food & Beverage$2,412 (97.8%)
Education$53.23 (2.2%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,412 | 95 | 97.8% |
| Education | $53.23 | 2 | 2.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $314.48 | 18 | $0 (2019) |
| Merck Sharp & Dohme LLC | $268.46 | 8 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $258.62 | 6 | $0 (2022) |
| Gilead Sciences, Inc. | $249.99 | 2 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $247.97 | 10 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $200.35 | 8 | $0 (2019) |
| Lilly USA, LLC | $132.88 | 2 | $0 (2023) |
| Celgene Corporation | $124.97 | 7 | $0 (2019) |
| Seattle Genetics, Inc. | $119.49 | 7 | $0 (2019) |
| GENZYME CORPORATION | $71.06 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $74.69 | 1 | Novartis Pharmaceuticals Corporation ($74.69) |
| 2023 | $309.89 | 3 | Merck Sharp & Dohme LLC ($187.97) |
| 2022 | $429.46 | 4 | Gilead Sciences, Inc. ($249.99) |
| 2020 | $31.24 | 2 | GlaxoSmithKline, LLC. ($16.88) |
| 2019 | $339.30 | 18 | E.R. Squibb & Sons, L.L.C. ($82.77) |
| 2018 | $707.76 | 38 | Genentech USA, Inc. ($227.62) |
| 2017 | $572.60 | 31 | Novartis Pharmaceuticals Corporation ($132.58) |
All Payment Transactions
97 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $74.69 | General |
| Category: Oncology | ||||||
| 05/17/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $67.15 | General |
| Category: ONCOLOGY | ||||||
| 03/01/2023 | Lilly USA, LLC | VERZENIO (Drug) | Food and Beverage | Cash or cash equivalent | $121.92 | General |
| Category: Oncology | ||||||
| 02/01/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $120.82 | General |
| Category: ONCOLOGY | ||||||
| 12/08/2022 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $113.27 | General |
| Category: Oncology | ||||||
| 08/17/2022 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: ONC | ||||||
| 08/03/2022 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $66.20 | General |
| Category: Oncology | ||||||
| 07/20/2022 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: ONC | ||||||
| 01/22/2020 | Coherus Biosciences Inc. | Udenyca (Biological) | Food and Beverage | In-kind items and services | $14.36 | General |
| Category: Granulocyte colony stimulating factor | ||||||
| 01/21/2020 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $16.88 | General |
| Category: ONCOLOGY | ||||||
| 11/26/2019 | Astellas Pharma US Inc | XTANDI (Drug) | Food and Beverage | In-kind items and services | $11.08 | General |
| Category: ONCOLOGY | ||||||
| 10/31/2019 | Celgene Corporation | Revlimid (Drug) | Food and Beverage | In-kind items and services | $17.50 | General |
| Category: Hematology / Oncology | ||||||
| 10/29/2019 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $11.62 | General |
| 10/23/2019 | Heron Therapeutics, Inc. | CINVANTI (Drug) | Food and Beverage | In-kind items and services | $18.79 | General |
| Category: CINV | ||||||
| 10/22/2019 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $11.16 | General |
| 10/07/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $11.34 | General |
| Category: Oncology | ||||||
| 10/01/2019 | Genentech USA, Inc. | Herceptin (Biological), Perjeta, Kadcyla | Food and Beverage | In-kind items and services | $14.56 | General |
| Category: BioOncology | ||||||
| 09/26/2019 | Lilly USA, LLC | ALIMTA (Drug), CYRAMZA, VERZENIO | Food and Beverage | In-kind items and services | $10.96 | General |
| Category: Oncology | ||||||
| 07/24/2019 | TerSera Therapeutics LLC | ZOLADEX (Drug) | Food and Beverage | In-kind items and services | $24.51 | General |
| Category: ONCOLOGY | ||||||
| 06/10/2019 | AMAG Pharmaceuticals, Inc. | FERAHEME (Drug), MUGARD | Education | In-kind items and services | $15.23 | General |
| Category: PARENTERAL IRON REPLACEMENT | ||||||
| 05/15/2019 | Seattle Genetics, Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $15.42 | General |
| Category: Oncology | ||||||
| 04/03/2019 | Seattle Genetics, Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $20.92 | General |
| Category: Oncology | ||||||
| 03/14/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $71.43 | General |
| Category: Oncology | ||||||
| 02/13/2019 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $22.04 | General |
| Category: Oncology | ||||||
| 02/06/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $11.40 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 332 | 613 | $180,976 | $65,101 |
| 2022 | 24 | 816 | 20,942 | $561,473 | $177,360 |
| 2021 | 38 | 1,652 | 79,686 | $2.6M | $911,091 |
| 2020 | 41 | 1,675 | 79,035 | $1.5M | $461,671 |
Total Patients
4,475
Total Services
180,276
Medicare Billing
$1.6M
Procedure Codes
111
All Medicare Procedures & Services
111 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 74 | 275 | $97,602 | $36,158 | 37.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 50 | 50 | $22,500 | $8,330 | 37.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 60 | 92 | $23,066 | $8,170 | 35.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 46 | 47 | $18,502 | $6,263 | 33.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 23 | 23 | $8,648 | $2,323 | 26.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 16 | 16 | $5,760 | $1,627 | 28.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 18 | 22 | $3,916 | $1,538 | 39.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 45 | 88 | $982.00 | $692.05 | 70.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 19 | 3,540 | $118,590 | $59,121 | 49.9% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2022 | 27 | 4,221 | $86,531 | $26,420 | 30.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 118 | 201 | $71,630 | $26,073 | 36.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 149 | 176 | $42,348 | $14,626 | 34.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 45 | 127 | $57,785 | $13,370 | 23.1% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2022 | 13 | 10,500 | $47,250 | $9,383 | 19.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 52 | 52 | $23,450 | $8,975 | 38.3% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2022 | 11 | 57 | $7,866 | $3,376 | 42.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 25 | 25 | $9,096 | $2,637 | 29.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 37 | 50 | $13,200 | $2,583 | 19.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 75 | 192 | $9,984 | $2,081 | 20.8% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2022 | 27 | 88 | $18,216 | $2,080 | 11.4% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2022 | 30 | 112 | $12,432 | $1,398 | 11.2% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2022 | 15 | 26 | $4,524 | $1,351 | 29.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 28 | 28 | $4,534 | $1,328 | 29.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 12 | 12 | $4,435 | $987.31 | 22.3% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2022 | 13 | 35 | $4,340 | $800.04 | 18.4% |
About Dr. Sri Lakshmi Hyndavi Yeruva, MD
Dr. Sri Lakshmi Hyndavi Yeruva, MD is a Hematology healthcare provider based in Chambersburg, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/15/2011. The National Provider Identifier (NPI) number assigned to this provider is 1801184577.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sri Lakshmi Hyndavi Yeruva, MD has received a total of $2,465 in payments from pharmaceutical and medical device companies, with $74.69 received in 2024. These payments were reported across 97 transactions from 29 companies. The most common payment nature is "Food and Beverage" ($2,412).
As a Medicare-enrolled provider, Yeruva has provided services to 4,475 Medicare beneficiaries, totaling 180,276 services with total Medicare billing of $1.6M. Data is available for 4 years (2020–2023), covering 111 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Hematology & Oncology, Medical Oncology
- Location Chambersburg, PA
- Active Since 07/15/2011
- Last Updated 12/20/2022
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1801184577
Products in Payments
- KEYTRUDA (Biological) $254.17
- Trodelvy (Drug) $249.99
- ENHERTU (Biological) $179.47
- OPDIVO (Biological) $138.14
- VERZENIO (Drug) $121.92
- ADCETRIS (Biological) $119.49
- Avastin (Biological) $117.09
- Perjeta (Biological) $105.95
- KISQALI (Drug) $98.95
- Revlimid (Drug) $76.69
- TASIGNA (Drug) $74.17
- Herceptin (Biological) $71.62
- JEVTANA (Drug) $71.06
- Rubraca (Drug) $64.72
- DARZALEX (Biological) $62.32
- EMPLICITI (Biological) $62.21
- JADENU (Drug) $58.97
- Venclexta (Drug) $42.74
- FASLODEX (Drug) $41.13
- Abraxane (Drug) $33.48
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.